Abstract
Background and aims: Management of familial hypercholesterolaemia (FH) may vary across different settings due to factors related to population characteristics, practice, resources and/or policies. We conducted a survey among the worldwide network of EAS FHSC Lead Investigators to provide an overview of FH status in different countries. Methods: Lead Investigators from countries formally involved in the EAS FHSC by mid-May 2018 were invited to provide a brief report on FH status in their countries, including available information, programmes, initiatives, and management. Results: 63 countries provided reports. Data on FH prevalence are lacking in most countries. Where available, data tend to align with recent estimates, suggesting a higher frequency than that traditionally considered. Low rates of FH detection are reported across all regions. National registries and education programmes to improve FH awareness/knowledge are a recognised priority, but funding is often lacking. In most countries, diagnosis primarily relies on the Dutch Lipid Clinics Network criteria. Although available in many countries, genetic testing is not widely implemented (frequent cost issues). There are only a few national official government programmes for FH. Under-treatment is an issue. FH therapy is not universally reimbursed. PCSK9-inhibitors are available in ∼2/3 countries. Lipoprotein-apheresis is offered in ∼60% countries, although access is limited. Conclusions: FH is a recognised public health concern. Management varies widely across countries, with overall suboptimal identification and under-treatment. Efforts and initiatives to improve FH knowledge and management are underway, including development of national registries, but support, particularly from health authorities, and better funding are greatly needed.
Original language | English |
---|---|
Journal | Atherosclerosis |
Volume | 277 |
Pages (from-to) | 234-255 |
Number of pages | 22 |
ISSN | 0021-9150 |
DOIs | |
Publication status | Published - 2018 |
Keywords
- Familial hypercholesterolaemia
- FHSC
- Primary dyslipidaemia
Access to Document
Fingerprint
Dive into the research topics of 'Overview of the current status of familial hypercholesterolaemia care in over 60 countries - The EAS Familial Hypercholesterolaemia Studies Collaboration (FHSC)'. Together they form a unique fingerprint.Cite this
- APA
- Standard
- Harvard
- Vancouver
- Author
- BIBTEX
- RIS
Overview of the current status of familial hypercholesterolaemia care in over 60 countries - The EAS Familial Hypercholesterolaemia Studies Collaboration (FHSC). / Vallejo-Vaz, Antonio J.; Marco, Martina De; Stevens, Christophe A.T. et al.
In: Atherosclerosis, Vol. 277, 2018, p. 234-255.Research output: Contribution to journal › Journal article › Research › peer-review
}
TY - JOUR
T1 - Overview of the current status of familial hypercholesterolaemia care in over 60 countries - The EAS Familial Hypercholesterolaemia Studies Collaboration (FHSC)
AU - Vallejo-Vaz, Antonio J.
AU - Marco, Martina De
AU - Stevens, Christophe A.T.
AU - Akram, Asif
AU - Freiberger, Tomas
AU - Hovingh, G. Kees
AU - Kastelein, John J.P.
AU - Mata, Pedro
AU - Raal, Frederick J.
AU - Santos, Raul D.
AU - Soran, Handrean
AU - Watts, Gerald F.
AU - Abifadel, Marianne
AU - Aguilar Salinas, Carlos A.
AU - Al-Khnifsawi, Mutaz
AU - Alkindi, Fahad A.
AU - Alnouri, Fahad
AU - Alonso, Rodrigo
AU - Al-Rasadi, Khalid
AU - Al-Sarraf, Ahmad
AU - Ashavaid, Tester F.
AU - Binder, Christoph J.
AU - Bogsrud, Martin P.
AU - Bourbon, Mafalda
AU - Bruckert, Eric
AU - Chlebus, Krzysztof
AU - Corral, Pablo
AU - Descamps, Olivier
AU - Durst, Ronen
AU - Ezhov, Marat
AU - Fras, Zlatko
AU - Genest, Jacques
AU - Groselj, Urh
AU - Harada-Shiba, Mariko
AU - Kayikçioglu, Meral
AU - Lalic, Katarina
AU - Lam, Carolyn S.P.
AU - Latkovskis, Gustavs
AU - Laufs, Ulrich
AU - Liberopoulos, Evangelos
AU - Lin, Jie
AU - Maher, Vincent
AU - Majano, Nelson
AU - Marais, David
AU - März, Winfried
AU - Mirrakhimov, Erkin
AU - Miserez, André R.
AU - Mitchenko, Olena
AU - Nawawi, Hapizah M.
AU - Nordestgaard, Børge G.
AU - Paragh, György
AU - Petrulioniene, Zaneta
AU - Pojskic, Belma
AU - Postadzhiyan, Arman
AU - Reda, Ashraf
AU - Reiner, Željko
AU - Sadoh, Wilson E.
AU - Sahebkar, Amirhossein
AU - Shehab, Abdullah
AU - Shek, Aleksander B.
AU - Stoll, Mario
AU - Su, Ta Chen
AU - Subramaniam, Tavintharan
AU - Susekov, Andrey V.
AU - Symeonides, Phivos
AU - Tilney, Myra
AU - Tomlinson, Brian
AU - Truong, Thanh Huong
AU - Tselepis, Alexandros D.
AU - Tybjærg-Hansen, Anne
AU - Vázquez-Cárdenas, Alejandra
AU - Viigimaa, Margus
AU - Vohnout, Branislav
AU - Widén, Elisabeth
AU - Yamashita, Shizuya
AU - Banach, Maciej
AU - Gaita, Dan
AU - Jiang, Lixin
AU - Nilsson, Lennart
AU - Santos, Lourdes E.
AU - Schunkert, Heribert
AU - Tokgözoğlu, Lale
AU - Car, Josip
AU - Catapano, Alberico L.
AU - Ray, Kausik K.
AU - Schreier, Laura
AU - Pang, Jing
AU - Dieplinger, Hans
AU - Hanauer-Mader, Gabriele
AU - Desutter, Johan
AU - Langlois, Michel
AU - Mertens, Ann
AU - Rietzschel, Ernst
AU - Wallemacq, Caroline
AU - Isakovic, Dzenana
AU - Dzankovic, Amra M.
AU - Obralija, Jasna
AU - Pojskic, Lamija
AU - Sisic, Ibrahim
AU - Stimjanin, Ena
AU - Torlak, Vildana A.
AU - Jannes, Cinthia E.
AU - Krieger, Jose E.
AU - Pereira, Alexandre C.
AU - Ruel, Isabelle
AU - Asenjo, Sylvia
AU - Cuevas, Ada
AU - Pećin, Ivan
AU - Miltiadous, George
AU - Panayiotou, Andrie G.
AU - Vrablik, Michal
AU - Benn, Marianne
AU - Heinsar, Silver
AU - Béliard, S.
AU - Gouni-Berthold, Ioanna
AU - Hengstenberg, Wibke
AU - Julius, Ulrich
AU - Kassner, Ursula
AU - Klose, Gerald
AU - König, Christel
AU - König, Wolfgang
AU - Otte, Britta
AU - Parhofer, Klaus
AU - Schatz, Ulrike
AU - Schmidt, Nina
AU - Steinhagen-Thiessen, Elisabeth
AU - Vogt, Anja
AU - Antza, Christina
AU - Athyros, Vasilios
AU - Bilianou, Eleni
AU - Boufidou, Amalia
AU - Chrousos, George
AU - Elisaf, Moses
AU - Garoufi, Anastasia
AU - Katsiki, Niki
AU - Kolovou, Genovefa
AU - Kotsis, Vasilios
AU - Rallidis, Loukianos
AU - Rizos, Christos
AU - Skalidis, Emmanouel
AU - Skoumas, Ioannis
AU - Tziomalos, Kostantinos
AU - Shawney, J. P.S.
AU - Abbaszadegan, Mohammad R.
AU - Aminzadeh, Majid
AU - Hosseini, Sousan
AU - Mobini, Moein
AU - Vakili, Rahim
AU - Zaeri, Hossein
AU - Agar, Ruth
AU - Boran, Gerard
AU - Colwell, Nial
AU - Crowley, Vivion
AU - Durkin, Maeve
AU - Griffin, Damian
AU - Kelly, Michael
AU - Rakovac-Tisdall, Ana
AU - Bitzur, Rafael
AU - Cohen, Hofit
AU - Eliav, Osnat
AU - Ellis, Avishay
AU - Gavish, Dov
AU - Harats, Dror
AU - Henkin, Yaacov
AU - Knobler, Hila
AU - Leavit, Leah
AU - Leitersdorf, Eran
AU - Schurr, Daniel
AU - Shpitzen, Shoshi
AU - Szalat, Auryan
AU - Arca, Marcello
AU - Averna, Maurizio
AU - Bertolini, Stefano
AU - Calandra, Sebastiano
AU - Tarugi, Patrizia
AU - Erglis, Andrejs
AU - Gilis, Dainus
AU - Nesterovics, Georgijs
AU - Saripo, Vita
AU - Upena-Roze, Arta
AU - Elbitar, Sandy
AU - Jambart, Sélim
AU - Khoury, Petra El
AU - Gargalskaite, Urte
AU - Kutkiene, Sandra
AU - Al-Khateeb, Alyaa
AU - An, Chua Y.
AU - Ismail, Zaliha
AU - Kasim, Sazzli
AU - Ibrahim, Khairul S.
AU - Radzi, Ahmad B.M.
AU - Kasim, Noor A.
AU - Nor, Noor S.M.
AU - Ramli, Anis S.
AU - Razak, Suraya A.
AU - Muid, Suhaila
AU - Rosman, Azhari
AU - Sanusi, Abd R.
AU - Razman, Aimi Z.
AU - Nazli, Sukma A.
AU - Kek, Teh L.
AU - Azzopardi, Conrad
AU - Aguilar Salinas, Carlos A.
AU - Galán, Gabriela
AU - Rubinstein, Ardon
AU - Magaña-Torres, M. T.
AU - Martagon, Alexandro
AU - Mehta, Roopa
AU - Wittekoek, M. E.
AU - Isara, Alphonsus R.
AU - Obaseki, Darlington E.
AU - Ohenhen, Oluwatoyin A.
AU - Holven, Kirsten B.
AU - Gruchała, Marcin
AU - Baranowska, Marlena
AU - Borowiec-Wolny, Justyna
AU - Gilis-Malinowska, Natasza
AU - Michalska-Grzonkowska, Aleksandra
AU - Pajkowski, Marcin
AU - Parczewska, Aleksandra
AU - Romanowska-Kocejko, Marzena
AU - Stróżyk, Aneta
AU - Żarczyńska-Buchowiecka, Marta
AU - Kleinschmidt, Mariola
AU - Alves, Ana C.
AU - Medeiros, Ana M.
AU - Ershova, Alexandra
AU - Korneva, Victoria
AU - Kuznetsova, Tatiana
AU - Malyshev, Pavel
AU - Meshkov, Alexey
AU - Rozhkova, Tatiana
AU - Popovic, Ljiljana
AU - Lukac, Sandra S.
AU - Stosic, Ljubica
AU - Rasulic, Iva
AU - Lalic, Nebojsa M.
AU - Chua, Terrance S.J.
AU - Ting, Sharon P.L.
AU - Raslova, Katarina
AU - Battelino, Tadej
AU - Cevc, Matija
AU - Jug, Borut
AU - Kovac, Jernej
AU - Podkrajsek, Katarina T.
AU - Sustar, Ursa
AU - Trontelj, Katja J.
AU - Marais, David
AU - Isla, Leopoldo Perez de
AU - Martin, François J.
AU - Charng, Ming Ji
AU - Chen, Pei Lung
AU - Kayikçioglu, Meral
AU - Dell’oca, Nicolás
AU - Fernández, Graciela
AU - Ressia, Andrés
AU - Reyes, Ximena
AU - Zelarayan, Mario
AU - Alieva, Rano B.
AU - Hoshimov, Shavkat U.
AU - Nizamov, Ulugbek I.
AU - Kurbanov, Ravshanbek D.
AU - Lima-Martínez, Marcos M.
AU - Nguyen, Mai Ngoc Thi
AU - Do, Doan Loi
AU - Kim, Ngoc Thanh
AU - Le, Thanh Tung
AU - Le, Hong An
PY - 2018
Y1 - 2018
N2 - Background and aims: Management of familial hypercholesterolaemia (FH) may vary across different settings due to factors related to population characteristics, practice, resources and/or policies. We conducted a survey among the worldwide network of EAS FHSC Lead Investigators to provide an overview of FH status in different countries. Methods: Lead Investigators from countries formally involved in the EAS FHSC by mid-May 2018 were invited to provide a brief report on FH status in their countries, including available information, programmes, initiatives, and management. Results: 63 countries provided reports. Data on FH prevalence are lacking in most countries. Where available, data tend to align with recent estimates, suggesting a higher frequency than that traditionally considered. Low rates of FH detection are reported across all regions. National registries and education programmes to improve FH awareness/knowledge are a recognised priority, but funding is often lacking. In most countries, diagnosis primarily relies on the Dutch Lipid Clinics Network criteria. Although available in many countries, genetic testing is not widely implemented (frequent cost issues). There are only a few national official government programmes for FH. Under-treatment is an issue. FH therapy is not universally reimbursed. PCSK9-inhibitors are available in ∼2/3 countries. Lipoprotein-apheresis is offered in ∼60% countries, although access is limited. Conclusions: FH is a recognised public health concern. Management varies widely across countries, with overall suboptimal identification and under-treatment. Efforts and initiatives to improve FH knowledge and management are underway, including development of national registries, but support, particularly from health authorities, and better funding are greatly needed.
AB - Background and aims: Management of familial hypercholesterolaemia (FH) may vary across different settings due to factors related to population characteristics, practice, resources and/or policies. We conducted a survey among the worldwide network of EAS FHSC Lead Investigators to provide an overview of FH status in different countries. Methods: Lead Investigators from countries formally involved in the EAS FHSC by mid-May 2018 were invited to provide a brief report on FH status in their countries, including available information, programmes, initiatives, and management. Results: 63 countries provided reports. Data on FH prevalence are lacking in most countries. Where available, data tend to align with recent estimates, suggesting a higher frequency than that traditionally considered. Low rates of FH detection are reported across all regions. National registries and education programmes to improve FH awareness/knowledge are a recognised priority, but funding is often lacking. In most countries, diagnosis primarily relies on the Dutch Lipid Clinics Network criteria. Although available in many countries, genetic testing is not widely implemented (frequent cost issues). There are only a few national official government programmes for FH. Under-treatment is an issue. FH therapy is not universally reimbursed. PCSK9-inhibitors are available in ∼2/3 countries. Lipoprotein-apheresis is offered in ∼60% countries, although access is limited. Conclusions: FH is a recognised public health concern. Management varies widely across countries, with overall suboptimal identification and under-treatment. Efforts and initiatives to improve FH knowledge and management are underway, including development of national registries, but support, particularly from health authorities, and better funding are greatly needed.
KW - Familial hypercholesterolaemia
KW - FHSC
KW - Primary dyslipidaemia
U2 - 10.1016/j.atherosclerosis.2018.08.051
DO - 10.1016/j.atherosclerosis.2018.08.051
M3 - Journal article
C2 - 30270054
AN - SCOPUS:85053666909
SN - 1567-5688
VL - 277
SP - 234
EP - 255
JO - Journal of atherosclerosis research
JF - Journal of atherosclerosis research
ER -